synaptonemal complex central element protein 3Genealiases: C22orf41 · THEG2
Q-omics provides the consensus-scored SYCE3 profile across patient tissues and cancer cell-line models. SYCE3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SYCE3 is differentially expressed in 16, with the highest sampling consensus in LIHC. Additionally, SYCE3 RNA expression shows 12,160 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LIHC, and TGCT as cancer lineages where SYCE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYCE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYCE3 survival associations across molecular data types. SYCE3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYCE3 RNA expression–survival associations across cancer types. High SYCE3 expression shows unfavorable associations in ACC, THYM and CHOL, but favorable associations in KIRP, READ and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SYCE3 RNA expression.
This table summarizes SYCE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SYCE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYCE3 shows higher tumor expression in LIHC, LUAD, BLCA, COAD, STAD and HNSC. The LIHC box plot shows higher SYCE3 RNA expression in tumor versus normal tissue (log2 FC = +0.899, t-test p < 0.001).
This table shows molecular features associated with SYCE3 in patient tissues and cancer cell lines. In patient samples, SYCE3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYCE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
